Vekariya, RH; Lei, W; Ray, A; Saini, SK; Zhang, SX; Molnar, G; Barlow, D; Karlage, KL; Bilsky, EJ; Houseknecht, KL; Largent-Milnes, TM; Streicher, JM; Ananthan, S in [Vekariya, Rakesh H.; Ray, Abhisek; Saini, Surendra K.; Zhang, Sixue; Ananthan, Subramaniam] Southern Res, Chem Dept, Birmingham, AL 35205 USA; [Lei, Wei; Molnar, Gabriella; Karlage, Kelly L.; Bilsky, Edward J.; Largent-Milnes, Tally M.; Streicher, John M.] Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA; [Barlow, Deborah; Houseknecht, Karen L.] Univ New England, Coll Osteopath Med, Dept Biomed Sci, Biddeford, ME 04005 USA published Synthesis and Structure-Activity Relationships of 5 ‘-Aryl-14-alkoxypyridomorphinans: Identification of a mu Opioid Receptor Agonist/delta Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects in 2020.0, Cited 65.0. Safety of 1,1,1-Triethoxyethane. The Name is 1,1,1-Triethoxyethane. Through research, I have a further understanding and discovery of 78-39-7.
We previously identified a pyridomorphinan (6, SRI-22138) possessing a 4-chlorophenyl substituent at the 5′-position on the pyridine and a 3-phenylpropoxy at the 14-position of the morphinan as a mixed mu opioid receptor (MOR) agonist and delta/kappa opioid receptor (DOR/KOR) antagonist with potent antinociceptive activity and diminished tolerance and dependence in rodents. Structural variations at the 5′- and 14-positions of this molecule gave insights into the structure-activity relationships for binding and functional activity. Subtle structural changes exerted significant influence, particularly on the ability of the compounds to function as agonists at the MOR. In vivo evaluation identified compound 20 (SRI-39067) as a MOR agonist/DOR antagonist that produced systemically active potent antinociceptive activity in tail-flick assay in mice, with diminished tolerance, dependence/withdrawal, reward liability, and respiratory depression versus morphine. These results support the hypothesis that mixed MOR agonist/DOR antagonist ligands may emerge as novel opioid analgesics with reduced side effects.
Welcome to talk about 78-39-7, If you have any questions, you can contact Vekariya, RH; Lei, W; Ray, A; Saini, SK; Zhang, SX; Molnar, G; Barlow, D; Karlage, KL; Bilsky, EJ; Houseknecht, KL; Largent-Milnes, TM; Streicher, JM; Ananthan, S or send Email.. Safety of 1,1,1-Triethoxyethane
Reference:
Thiazolidine – Wikipedia,
,Thiazolidine – ScienceDirect.com